Biochemical and clinical effects of tyrosine and tryptophan in the Rett syndrome

Brain Dev. 1990;12(1):143-7. doi: 10.1016/s0387-7604(12)80197-5.

Abstract

In the Rett syndrome (RS), a progressive encephalopathy affecting girls, deficient neurotransmitter synthesis has been suggested as a pathogenetic mechanism. Nine girls with RS were treated with 0.3 g of tyrosine and 0.1 g of tryptophan per kg body weight for 2 to 17 weeks. This resulted in a median rise in the spinal fluid concentration of the dopamine metabolite homovanillic acid by 31%, and of the serotonin metabolite 5-hydroxyindoleacetic acid by 40%. This finding supports the hypothesis of a compromised neurotransmitter synthesis and indicates that it can be stimulated by supply of amino acid precursors. A double-blind cross-over trial including 11 girls did not show clinical improvement during a treatment period of 8 to 10 weeks.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Child
  • Dopamine / metabolism
  • Double-Blind Method
  • Female
  • Homovanillic Acid / cerebrospinal fluid*
  • Humans
  • Hydroxyindoleacetic Acid / cerebrospinal fluid*
  • Rett Syndrome / drug therapy*
  • Rett Syndrome / metabolism
  • Tryptophan / therapeutic use*
  • Tyrosine / therapeutic use*

Substances

  • Tyrosine
  • Hydroxyindoleacetic Acid
  • Tryptophan
  • Dopamine
  • Homovanillic Acid